|Daily Range||$2.50 - $2.62|
|52-Week Range||$2.22 - $5.52|
|Dividend (Yield)||$0.00 (0.0%)|
|Average Daily Volume||1,097,943|
|Current FY EPS||-$0.83|
A double dose of bad news for the obesity drugmaker.
Orexigen Therapeutics is crashing today following more bad news for its diet pill Contrave. Here's what investors need to know right now.
Orexigen Therapeutics shares tumble after the company announces the termination of a critical post-marketing approval study for Contrave.